Neurocrine - Ingrezza

“Spotlight”

Director

Working with the Chief Scientific Officer and the Neurocrine team was exciting to learn about the pharmaceutical, Ingrezza, and how it can change people’s lives who are dealing with Tardive Dyskinesia (TD). TD is a condition affecting the nervous system with uncontrollable, abnormal and repetitive movements of the face, torso and/or other body parts – often caused by long-term use of some psychiatric drugs.

Ingrezza is a prescribed oral medication which is intended to treat adults who suffer from Tardive Dyskinesia by reducing dopamine signaling when taken regularly as suggested. Ingrezza is thought to work by reducing the amount of dopamine released in a region of the brain that controls movement and motor function, helping to regulate nerve signaling.